SOLICITATION NOTICE
A -- In Vitro and Animal Models for Emerging Diseases and Biodefense
- Notice Date
- 9/25/2002
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institutes of Allergy and Infectious Diseases, Contract Management Branch 6700 B Rockledge Room 2230 MSC7612, Bethesda, MD, 20892-7605
- ZIP Code
- 20892-7605
- Solicitation Number
- RFP-NIH-NIAID-DMID-03-39
- Point of Contact
- Paul McFarlane, Senior Contracting Officer, Phone 301-496-0349, Fax 301-402-0972, - Paul McFarlane, Senior Contracting Officer, Phone 301-496-0349, Fax 301-402-0972,
- E-Mail Address
-
pm24v@nih.gov, pm24v@nih.gov
- Description
- The National Institute of Allergy and Infectious Diseases intends this contract to provide targeted screening to identify potential therapeutic and preventive modalities, as well as resources to characterize additional antimicrobial activities of already licensed antimicrobial agents, small animal and non-human primate models to test the safety and efficacy of therapeutic and preventive modalities that target emerging infectious agents including, Bioterrorism Category A-C agents as outlined in the CDC website http://www.bt.cdc.gov/Agent/Agentlist.asp. A list of priority organisms is also available on the NIAID website http://www.niaid.nih.gov/dmid/biodefense/bandc_priority.htm. The objective of this contract is to provide a range of developmental resources to bring new therapies and preventive measures from the laboratory to initial clinical testing in humans. The contract consists of six parts, listed below, which each contribute to the overall development effort. These contracts will provide a ready capacity in a number of needed areas and will be utilized as products become available for testing. Test articles that are found to have activity in Part A may progress through development using contractors from other parts. For Parts C, D, E and F, various vaccine concepts may be tested based on the following categories: (a) synthetic peptides, (b) recombinant subunits, (c) vector based vaccines, (d) virus-like particles/replicons, or (e) nucleic acid based vaccines. The contract will have six (6) parts. Part A: In Vitro Screens for Antimicrobial Activity. Part A will provide the capacity to screen test articles for antimicrobial activity against emerging infectious agents including, Bioterrorism Category A-C agents. Materials for testing will be obtained by NIAID and provided to the contractor for testing. This contract is not intended to cover antiviral screening against viral hemorrhagic fevers or poxviruses, which is covered by a separate contract. Part B: Clinical Isolate Panels for Selected Bacterial Pathogens. Part B will provide the capacity to perform antimicrobial activity determination against clinical panels of bacterial pathogens to arrive at tentative susceptibility breakpoints. This activity is to be performed using bacterial pathogens classified as emerging infectious agents, including Bioterrorism Category A-C agents. Antimicrobial agents to be tested under this contract will be selected on the basis of their activity against select genera and species of bacterial pathogens using reference strains. Part C: Small Animal Models for Selected Pathogens, including GLP Studies. Part C will support the development, validation and use of various small animal models to screen new therapeutic, diagnostic and preventive agents or test the efficacy of therapeutics, immunotherapies, diagnostics, and vaccines with activity against emerging infectious agents including, Bioterrorism Category A-C agents. Part D: Non-human Primate Models for Selected Pathogens, including GLP Studies. Part D will support the development, validation and use of various non-human primate models to screen new therapeutic, diagnostic and preventive agents or test the efficacy of therapeutics, immunotherapies, diagnostics, and vaccines with activity against emerging infectious agents including, Bioterrorism Category A-C agents. Part E: Safety and Immunogenicity Testing for Vaccines. Part E will support the testing of vaccine preparations as required prior to initial clinical evaluation (under GLP). This includes testing candidate products for safety and immunogenicity (both cellular and humoral) in small animals and, if appropriate, in non-human primates. Part F: Safety/Toxicology and Pharmacology Testing for Therapeutics. Part F will support the testing of candidate products for safety, including reproductive toxicology and other appropriate tests, in small and large animal, and if necessary, in non-human primates. This activity includes all such tests as are required to support clinical use in humans; testing must be sufficient to meet requirements for IND filing (GLP). It is anticipated that multiple awards will be made for each part of this Indefinite Delivery Indefinite Quantity (IDIQ) solicitation. The ordering period of this IDIQ will be in effect for seven (7) years. An IDIQ contract provides for an indefinite quantity, within stated limits, of supplies or services to be furnished during a fixed period, with deliveries or performance to be scheduled by the Government placing orders with the contractor. Task orders will be issued to the pre-qualified pool of contractors for parts A, B, C, D, E or F based on the specific requirements of the task order. The RFP contains at least one actual task for each of these six parts. In response to this RFP, potential Offerors may submit proposals for one or more of the six Parts described above. For Parts A and B, Offerors should propose as many organisms or groups of organisms as possible. Within Parts C, and D Offerors may submit proposals for one or more of the models using the same organisms/disease or models for more than one organism/disease. Offerors for Parts E and F should propose a comprehensive services to cover all aspects of the Statement of Work. Proposals will undergo peer review based on the evaluation criteria and awards will be made to the most qualified proposals. Each Offeror awarded a contract under a given Part or Category, will receive a guaranteed minimum dollar award over the term of the Contract. The following scale will determine the guaranteed minimum dollar awards for each part: Part A $ 75,000 Part B $ 75,000 Part C $100,000 Part D $150,000 Part E $100,000 Part F $100,000 NIAID anticipates award of one IDIQ contract beginning approximately September 30, 2003. RFP NIH-NIAID-DMID-03-39 will be available electronically on or about September 30, 2002, and may be accessed through the NIAID Contract Management Branch (CMB) Home page at http://www.niaid.nih.gov/cgi-shl/cmb/rfps.cfm. Please note that the RFP for this acquisition will only includes the work statement, deliverable and reporting requirements, special requirements, the technical evaluation criteria, and the proposal preparation instructions. All information required for the submission of an offer will be contained in the electronic RFP package. Following proposal submission and the initial review process, Offerors comprising the competitive range will be asked to provide additional documentation to the Contracting Officer. Responses to this RFP will be due approximately January 30, 2003. Any responsible Offeror may submit a proposal, which will be considered by the Government. This advertisement does not commit the Government to award a contract. Point of contact: Paul McFarlane, Contracting Officer, Phone (301) 496-0349 or FAX 301-402-0972 or via email pm24@nih.gov. No collect calls will be accepted.
- Place of Performance
- Address: To Be Determined
- Zip Code: TBD
- Country: TBD
- Zip Code: TBD
- Record
- SN00175399-W 20020927/020925213906 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |